Abstract
Sixteen patients who underwent a second allogeneic hematopoietic stem cell transplantation (HSCT2) for leukemia relapse after the first allogeneic transplantation (HSCT1) were studied. The patients included 7 patients with acute myelogenous leukemia, 8 with acute lymphoblastic leukemia, and 1 with chronic myelogenous leukemia.The median patient age at HSCT2 was 22 years (range, 12 to 44 years).The median interval between HSCT1 and HSCT2 was 19 months (range, 2 to 46 months). At HSCT2, 7 patients were in complete remission (CR), 7 had relapsed, and 2 had bone marrow aplasia. In 14 patients, donors for HSCT2 were the same as those for HSCT1. Two donors were replaced, 1 for another HLA-matched sibling and 1 for an unrelated cord blood donor. Four patients (25%) died within 100 days after HSCT2 from veno-occlusive disease, sepsis, interstitial pneumonitis, or chronic graft-versus-host disease (GVHD), without leukemia relapse. Seven patients (44%) developed leukemia relapse and died between 4 and 20 months after HSCT2. Five patients (31%) survived beyond 4 years. One patient died from chronic GVHD without leukemia relapse 55 months after HSCT2. The 4 other patients were alive between 79 and 134 months after HSCT2 (median follow-up, 106 months). Factors that favorably influenced survival were age younger than 20 years and CR duration after HSCT1 longer than 12 months. HSCT2 is considered to be beneficial for select patients. Preparative regimens, GVHD prophylaxis, and donor choice for HSCT2 need to be studied to obtain a more successful outcome for HSCT2.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kumar L. Leukemia: management of relapse after allogeneic bone marrow transplantation.J Clin Oncol. 1994;12:1710–1717.
Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review.Blood. 1994;84:3603–3612.
Kishi K, Takahashi S, Gondo H, et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes.Bone Marrow Transplant. 1997;19:461–466.
Barrett AJ, Locatelli F, Treleaven JG, et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party.Br J Haematol. 1991;79:567–574.
Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens.J Clin Oncol. 1993;11:304–313.
Chiang KY, Weisdorf DJ, Davies SM, et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse.Bone Marrow Transplant. 1996;17:39–42.
Mrsic M, Horowitz MM, Atkinson K, et al. Second HLA-identical sibling transplants for leukemia recurrence.Bone Marrow Transplant. 1992;9:269–275.
Wagner JE, Vogelsang GB, Zehnbauer BA, et al. Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy.Bone Marrow Transplant. 1992;9:205–209.
McDonald GB, Sharma P, Matthews DE, et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.Hepatology. 1984;4:116–122.
Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation.J Clin Oncol. 1988;6:1562–1568.
Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading.Bone Marrow Transplant. 1995;15:825–828.
Hackman R, Tsoi MS, Storb R, Thomas ED. Chronic graft-versushost syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.Am J Med. 1980;69:204–217.
Bosi A, Bacci S, Miniero R, et al. Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO).Leukemia. 1997;11:420–424.
Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.J Clin Oncol. 1997;15:433–444.
Shiobara S, Nakao S, Ueda M, et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.Bone Marrow Transplant. 2000;26:769–774.
Michallet M, Tanguy ML, Socie G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM).Br J Haematol. 2000;108:400–407.
Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.Blood. 1997;89:4531–4536.
Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.Blood. 1998;91:756–763.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tomonari, A., Iseki, T., Ooi, J. et al. Second Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia Relapse After First Allogeneic Transplantation: Outcome of 16 Patients in a Single Institution. Int J Hematol 75, 318–323 (2002). https://doi.org/10.1007/BF02982050
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02982050